Collaboration Shows Vaccine Candidate Can Produce Powerful ‘Broadly Neutralizing Antibodies’ in Animal Models
Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.
“This study shows that we’re moving in the right direction for a universal flu vaccine,” said Ian Wilson, Hansen Professor of Structural Biology and chair of the Department of Integrative Structural and Computational Biology at TSRI.
The study was part of TSRI’s long-term collaboration to strengthen research against infectious disease with the former Crucell Vaccine Institute, now known as Janssen Prevention Center and headquartered in Leiden, the Netherlands.
The research was published online ahead of print on August 24 by the journal Science.
The Need for Better Flu Shots
Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in the United States, according to the U.S. Centers for Disease Control and Prevention. While a yearly flu shot provides some protection, subtypes not covered by the vaccine can emerge rapidly. This phenomenon was evident in the 2009 spread of the H1N1 (“swine flu”) subtype that killed an estimated 151,700 to 575,400 people worldwide.
In the last decade, several studies from TSRI, Janssen and other institutions have shown that some people are capable of making powerful antibodies that can fight many subtypes of influenza at once by targeting a site on the influenza virus that does not mutate rapidly. Unfortunately, these “broadly neutralizing antibodies,” or bnAbs, are rare.
Still, the tantalizing existence of broadly neutralizing antibodies led Janssen and TRSI to try creating an influenza vaccine specially designed to elicit them.
Researchers zeroed in on a possible target: a protein on the surface of influenza, called hemagglutinin (HA). HA is present on all subtypes of influenza, providing the key viral “machinery” that enables the virus to enter cells. Most importantly, the long “stem” region of HA, which connects the virus to cells, plays such a crucial role that mutations at the site are unlikely to be passed on.
“If the body can make an immune response against the HA stem, it’s difficult for the virus to escape,” Wilson explained.
Fighting ‘Bird Flu’ and Other Strains
To create antibodies against the HA stem, the research team looked to influenza’s own structure, specifically the universal recognition site of the broadly protective antibody CR9114 in the HA stem (described by Dreyfus et al., Science 2012). This vaccine candidate was designed, produced and tested by a team of scientists led by Jaap Goudsmit, head of the Janssen Prevention Center, the paper’s first author Antonietta Impagliazzo (responsible for the design) and co-senior author Katarina Radoševi?.
The effort represents the first time scientists have been able to cut off the variable head region of HA, designing features able to stabilize the conformation of the original protein, and at the same time faithfully mimicking the key broadly neutralizing site. The ultimate goal was to use this synthetic version of the HA stem in a vaccine to teach the body to make powerful antibodies against influenza virus, priming it to fight off a variety of flu strains.
The scientists then studied the response of rodent and nonhuman primate models given one of several candidate immunogens. They found that animals given one especially stable immunogen produced antibodies that could bind with HAs in many influenza subtypes, even neutralizing H5N1 viruses (“avian” or “bird” flu).
“This was the proof of principle,” said Wilson. “These tests showed that antibodies elicited against one influenza subtype could protect against a different subtype.”
Scientists at TSRI studied the structure of the immunogen at every point in the process. Using the imaging techniques of electron microscopy (led by TSRI Associate Professor Andrew Ward and postdoctoral fellow Ryan Hoffman) and x-ray crystallography (led by Wilson and TSRI Staff Scientist Xueyong Zhu), the team showed that the most promising candidate immunogen mimicked the HA stem and that antibodies could bind with the immunogen just as they would with a real virus.
With proof that an immunogen can elicit antibodies against the stem region, Wilson said the next step in this research is to see if the immunogen can do the same in humans.
“While there is more work to be done, the ultimate goal, of course, would be to create a life-long vaccine,” Wilson said.
The Latest on: Universal flu vaccine
[google_news title=”” keyword=”Universal flu vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Universal flu vaccine
- How effective is this year’s flu shot? CDC explains.on February 29, 2024 at 2:28 pm
(The Hill) — This season’s influenza shots have so far been 42 percent effective, which is consistent with recent years, the Centers for Disease Control and Prevention (CDC) said this week. The CDC’s ...
- RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggeston February 29, 2024 at 1:58 pm
The new vaccines that protect older adults against RSV may be linked to a small increased risk of developing Guillain-Barré syndrome, new data suggest.
- Immunity vaccines for elderly soon in Keralaon February 28, 2024 at 8:28 pm
In the initial phase, the vaccines will be made available with the cooperation of private hospitals at low prices ...
- Novel Hexaplex Vaccine Promises Broad Flu Protectionon February 24, 2024 at 2:02 am
Discover the new nanoliposome flu vaccine with promising animal model results with enhanced protection against prevalent flu strains.
- Urgent action needed to prevent a measles epidemic in Aotearoa New Zealandon February 21, 2024 at 5:37 pm
To prevent a measles epidemic urgent steps are needed to catch up those who have missed out on vaccination, alongside continuing work to increase routine childhood coverage, particularly for Māori, ...
- Understanding guaranteed universal life insuranceon February 21, 2024 at 4:00 pm
Guaranteed universal life insurance has fixed premiums over your lifetime. With guarantee periods between 90 and 121 years, the policy typically outlasts the policyholder, all but guaranteeing the ...
- Why are Indians falling ill so frequently?on February 20, 2024 at 8:28 pm
Greater incidence of influenza could be linked to evolving strains of influenza virus, antimicrobial resistance ...
- What Is Universal Life Insurance? Explainedon February 19, 2024 at 7:32 pm
Ashley is a personal finance writer and content creator. In addition to being a contributing writer at Forbes, she writes for solo entrepreneurs as well as for Fortune 500 companies. Through her ...
- The Ins and Outs of Universal Childhood Influenza Vaccinationon February 18, 2024 at 4:00 pm
Seasonal influenza vaccine efficacy in young healthy children has been tested in multiple clinical studies and trials. In most of these studies, differences in the proportion of children with ...
- Can Hong Kong play a leading role in creating longer-lasting flu vaccines? Researchers to join up with global experts and give it a shot, Post learnson February 13, 2024 at 2:36 am
Hong Kong medical researchers will be working with international experts to develop two vaccines that provide protection against more strains of influenza virus and also last longer, the Post has ...
via Bing News